9 News & Press Releases found

Exscientia news

Exscientia enters $70M collaboration to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential

Four-year agreement with Bill & Melinda Gates Foundation to discover and develop small molecule therapeutics with less susceptibility to variants and greater patient access than current approaches --
Exscientia to use leading AI platform and in-house drug expertise to discover and develop five phase 1-ready assets; Gates Foundation to contribute sector expertise in antivirals and global public health --
Investment accelerates Exscientia’s Mpro coronavirus

Sep. 2, 2021

Exscientia Announces Closing of $510.4 Million Aggregate Financing, Consisting of $350.4 Million Upsized Initial Public Offering with Full Exercise of Underwriters’ Option to Purchase Additional ADSs and $160.0 Million Concurrent Private Placement

OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the closing of its previously-announced upsized initial public offering in the United States of 15,927,500 American Depositary Shares (“ADSs”) representing 15,927,500 ordinary shares, including 2,077,500 ADSs sold pursuant to the full exerc

Oct. 1, 2021

Exscientia Announces Pricing of $304.7 Million Upsized Initial Public Offering and $160.0 Million Concurrent Private Placements

OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the pricing of its upsized initial public offering in the United States of 13,850,000American Depositary Shares (“ADSs”) representing 13,850,000 ordinary shares at an initial public offering price of $22.00 per ADS, for total gross proceeds

Sep. 3, 2021

Bristol Myers Squibb exercises option to develop Exscientia’s AI-designed, immune-modulating drug candidate

First candidate in multi-target collaboration to reach in-license milestone

BMS to take responsibility for clinical and commercial development

Exscientia receives $20 million option exercise fee with additional development milestones as well as tiered royalties on product sales

OXFORD, U.K. – August 18, 2021 – Exscientia, a clinical-stage, artificial intelligence (AI)-driven pharmatech company,

Aug. 2, 2021

Exscientia and GT Apeiron Therapeutics Enter Oncology Joint Venture

Combines Exscientia’s leading AI-driven drug identification and design capabilities with GT Apeiron’s expertise in cyclin-dependent kinase (CDK) targets for oncology.

Expands existing CDK7 drug discovery partnership with additional CDK targeting drugs

Oxford & Shanghai – July 21st, 2021 – Exscientia, an AI-driven pharmatech company with a mission to revolutionise how drugs are discovered, and GT Apeiron Therapeutics (Apeiron), a Sh

Jul. 2, 2021